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Abstract
Background: Artemisinin-based combination therapy, currently considered the therapy of choice for
uncomplicated Plasmodium falciparum malaria in endemic countries, may be under threat from newly emerging
parasite resistance to the artemisinin family of drugs. Studies in Southeast Asia suggest some patients exhibit an
extended parasite clearance time in the three days immediately following treatment with artesunate monotherapy.
This phenotype is likely to become a more important trial endpoint in studies of anti-malarial drug efficacy, but
currently requires frequent, closely spaced blood sampling in hospitalized study participants, followed by
quantitation of parasite density by microscopy.
Methods: A simple duplex quantitative PCR method was developed in which distinct fluorescent signals are
generated from the human and parasite DNA components in each blood sample. The human amplification target
in this assay is the b tubulin gene, and the parasite target is the unique methionine tRNA gene (pgmet), which
exhibits perfect sequence identity in all six Plasmodium species that naturally infect humans. In a small series of
malaria cases treated as hospital in-patients, the abundance of pgmet DNA was estimated relative to the human
DNA target in daily peripheral blood samples, and parasite clearance times calculated.
Results: The qPCR assay was reproducibly able to replicate parasite density estimates derived from microscopy, but
provided additional data by quantification of parasite density 24 hours after the last positive blood film. Robust
estimates of parasite clearance times were produced for a series of patients with clinical malaria.
Conclusions: Large studies, particularly in Africa where children represent a major proportion of treated cases, will
require a simpler blood sample collection regime, and a method capable of high throughput. The duplex qPCR
method tested may fulfil these criteria, and should now be evaluated in such field studies.
Background
Artemisinin-based combination therapy (ACT) is cur-
rently considered the best treatment for uncomplicated
Plasmodium falciparum malaria [1]. The artemisinin
component of these combinations produces a character-
istic rapid reduction in parasite biomass immediately
after treatment, but these compounds are metabolized
in hours, and thus combination with a partner drug is
required to provide complete parasite clearance with
short treatment regimens, and to minimize the opportu-
nity for evolution of parasites resistant to either compo-
nent drug [2,3]. Recently, however, there have been
reports of a decline of ACT efficacy, manifested as
slower parasite clearance than expected in a significant
subset of patients receiving artemisinin monotherapy,
and ACT, in Western Cambodia [4-6].
In areas where ACT is deployed as the major anti-
malarial treatment option, early warning of any decrease
in the rate of parasite clearance in treated patients would
enable adequate countermeasures to be taken to prevent
onward transmission of these potentially resistant para-
sites, and to facilitate the search for genetic markers
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associated with this newly recognized parasite phenotype.
In an individual, the persistence of parasites to day 3 fol-
lowing chemotherapy is a reliable predictor of subse-
quent treatment failure [7], and thus a marker for this
would assist in the rational use of alternative treatment
regimens to prevent prolonged parasite carriage, and
enhanced transmission of novel parasite genotypes [8].
Parasite Clearance Time (PCT) is estimated by mea-
suring change in peripheral parasitaemia in a sequence
of samples taken after treatment, typically for 72 hours,
and currently this requires microscopic examination of
blood films. However, accurate microscopic estimation
of parasite density requires considerable expertise; false
negatives can easily be read especially at low-level para-
sitaemia; it is labour intensive and suffers from low
throughput. Further, as the majority of ACT-treated
patients are free of parasitaemia by microscopy within
48 hours of treatment, many closely-spaced venous
blood samples in catheterized in-patients have been
taken in previous studies to obtain a useful estimate of
PCT by this method [5,6]. This approach is not suitable
for large clinical trials, particularly in African settings,
where the majority of participants are likely to be outpa-
tients under the age of 10 years; such excessive sampling
would be considered unethical in most such studies. A
simple, rapid method for estimating PCT that did not
require multiple venous blood samples, but could be
achieved with relatively few finger-prick blood samples,
spotted and dried on filter paper for storage, would thus
be a useful new tool for large African studies of anti-
malarial efficacy. However, absolute quantitation of
parasite density from dried filter-paper blood spots is
difficult, as the volume of blood in each spot is usually
not known, and the efficiency of DNA extraction and
target amplification differs between paper types and
even among individual patients [9].
This paper reports the development and use of a new
duplex quantitative real-time PCR (qPCR) assay to mea-
sure parasite clearance after anti-malarial treatment. To
overcome problems with absolute parasite quantitation
in the intended future application to DNA extracted
from dried filter paper blood spots, parasite DNA abun-
dance is normalized to a human white blood cell DNA
target in the same sample, permitting calculation of rela-
tive parasite density in each sequential patient sample by
the delta-delta CT (ΔΔCT) method [10]. The time
required to clear 95% of the parasites (PCT95), and the
ratio in parasite density between admission and 48
hours post-treatment, or parasite reduction ratio
(PRR48), are then easily derived. These parameters were
used to compare treatment response among patients
treated with different anti-malarial regimens at the Hos-
pital for Tropical Diseases (HTD), London.
Methods
Samples and patients
Parasitized peripheral blood was obtained from malaria
patients admitted to HTD, as part of routine in-patient
care [11]. Samples were collected on admission and
approximately every 24 hours until cleared from the
peripheral blood after treatment. Written informed con-
sent was given by patients 1, 2 and 3 for additional bio-
logical studies of malaria parasites isolated from their
blood samples to be carried out, according to a protocol
approved by the University College London Hospital
(UCLH) Research Ethics Committee (ref. 07/Q0505/60).
Parasite isolates from patient 4 were investigated in
detail at the specific request of the attending physician,
as a suspected case of quinine treatment failure.
For each sample, DNA was purified from an aliquot of
200 μL of peripheral blood collected in EDTA, using the
Qiagen QIAamp blood extraction kit and was eluted in a
volume of approximately 100 μl [11]. In addition, for
patients 1, 2 and 3 between 2.5 mL and 4.0 mL of pre-
treatment (day 0) leuco-depleted blood was prepared and
DNA extracted using the Qiagen maxi extraction kit.
P. falciparum genome sequence data was generated from
these samples using the Solexa Illumina platform at the
Wellcome Trust Sanger Institute (WTSI), Hinxton, Cam-
bridgeshire. These data, for patients 1, 2 and 3, are freely
available via the MapSeq software platform at WTSI,
designated OX007, OX005 and OX006, respectively [12].
PCT using microscopy
Microscopic examinations of thick and thin smears,
stained by the rapid Field’s method for diagnosis and esti-
mate of parasite density, and Giemsa-stained for discrimi-
nation of Plasmodium species, were performed according
to standard methods by at least two experienced micro-
scopists. This was performed in the Department of Clini-
cal Parasitology at HTD, a fully accredited diagnostic
laboratory that undergoes external quality assurance as a
participant in the UK National External Quality Assess-
ment Scheme for Parasitology. Parasite density is
expressed as the percentage of erythrocytes which carry
asexual stages of P. falciparum. The density of Plasmo-
dium ovale curtisi parasites in patient 1 was not specifi-
cally measured by the microscopists, but was estimated to
be less than 1% of total parasitaemia, P. falciparum being
dominant at all time points.
Designing primers and probes
Specific primer pairs and double-labelled fluorescent
hydrolysis probes were designed using Primer Express
software (AP Applied Biosystems) to amplify part of the
Plasmodium tRNA methionine (PgMET) gene, which
exhibits 100% sequence identity between Plasmodium
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vivax and P. falciparum (Genbank accession numbers:
AL844509, nt 1575551-1575622; AZ570363, nt 127-56).
Primers based on these sequences successfully amplified
a fragment of pgmet from P. ovale curtisi, Plasmodium
ovale wallikeri [13], Plasmodium malariae and Plasmo-
dium knowlesi DNA. The identity of the PCR target was
confirmed by direct sequencing for each species. Thus it
was concluded that this amplicon was suitable for cross-
species parasite quantitation, under the assumption that
each species had a single copy of the pgmet gene.
The human b tubulin gene (HumTuBB; Genbank
accession no. NM_030773) was chosen as the endogen-
ous normalizing gene for human white blood cell DNA,
and a suitable PCR amplicon with internal probe
sequence was identified using Primer Express. The pri-
mer and probe sequences for both PgMET and Hum-
TuBB are given in Table 1.
A 20 μl PCR master mix was prepared as follows:
5.5 mM MgCl2 buffer (Bioline), 0.3 mM dNTPs (Bio-
line), 0.3 μM forward and reverse primers, 0.2 μM of
each probes (MWG-Biotech), 10× NH4 buffer (Bioline),
1.0 unit of BIOTAQ™ DNA polymerase (Bioline) and
molecular grade water. 5 μl DNA was added and a total
of 25 μl reaction was run in a Rotorgene 3000 thermo-
cycler (Corbett, Australia). A cut off of 40 cycles was
used to define positive samples. International Standard
(INT) for P. falciparum DNA [14], which contains white
blood cell DNA from the original donor specimen, was
used as a positive control while parasite negative blood
and water were used as negative controls. All reactions
were performed in triplicate. The amplification and flor-
escence detection was performed with the following
two-step conditions: 95°C for 6 min; 40 cycles of 95°C
for 15 s and 68°C for 1 min.
Results
Case descriptions
Patient 1 (OX007) presented with symptomatic malaria
at HTD after returning from attending school in Lagos,
Nigeria, and was found to harbour a mixed infection of
P. falciparum (at 3.2% parasitaemia) and both gameto-
cytes and trophozoites of P. ovale curtisi (at less than
0.03% parasitaemia), confirmed by PCR. The patient was
treated with intravenous (i.v.) quinine (QN) for 1 day,
oral QN for 5 days and given a full dose of sulphadox-
ine-pyrimethamine on discharge.
Patient 2 (OX005) developed symptomatic malaria
after visiting Ghana, presenting to a local clinic in outer
London one week after symptoms began. Unfortunately,
treatment was further delayed due to a misdiagnosis of
pandemic influenza (H1N1). The patient was seen again
after four days and was immediately hospitalized, with
the following signs of severe falciparum malaria: renal
function impairment, hepatic function impairment,
acidosis, antigen test for P. falciparum positive. The
patient was started on i.v. QN, and blood films were
taken and sent by courier to HTD. A diagnosis of falci-
parum malaria was confirmed by the on-call parasitol-
ogy biomedical scientist, with a parasitaemia of 3%. The
patient’s condition had further deteriorated and transfer
to the Intensive Care Unit (ICU) at HTD was arranged.
Therapy with i.v. QN was continued for five days, and
metabolic derangements gradually improved under ICU
management. By the fourth day of treatment, only
gametocytes of P. falciparum were observed on blood
films. Five sequential daily blood samples were available.
Patient 3 (OX006) spent two weeks in Kenya based in
Nairobi, and visiting Lake Naivasha, an area considered
low risk for malaria. On advice, no prophylaxis was
taken. The patient presented at night to a hospital out-
side London, and was antigen test positive for P. falci-
parum. Blood-films were taken and immediately
couriered to the on-call parasitology biomedical scientist
who identified extreme hyperparasitaemia of P. falci-
parum (approximately 2 × 106 parasites μl-1; 39% parasi-
taemia). To ensure early commencement of treatment,
prior to transfer of the patient, the same motorcycle
courier was dispatched in haste back to the referring
hospital with i.v. artesunate (AS), which was adminis-
tered just prior to departure for HTD. The patient was
transferred to ICU, and treatment with i.v. AS contin-
ued. The patient exhibited the following signs of severe
malaria: severe acidosis, renal impairment, deranged
hepatic function, respiratory distress and haematuria.
Remarkably, the patient remained conscious and lucid
throughout his period of care in ICU. Haemofiltration
was required for renal failure, but the initially high para-
sitaemia fell rapidly under treatment. AS was given up
Table 1 Amplification primers and double-labelled hydrolysis probes for PgMET and HumTuBB
Primer/Probe 5’ Fluorophore Sequence 3’ Quencher
PgMET_F1 5’-TGAAAGCAGCGTAGCTCAGA
PgMET_R2 5’-CGCGTGGTTTCGATCCACG
PgMET_pB FAM 5’-GGGGCTCATAACCCCCAGGA BHQ2
HumTuBB_F2 5’-AAGGAGGTCGATGAGCAGAT
HumTuBB_R2 5’-GCTGTCTTGACATTGTTGGG
HumTuBB_Joe JOE 5’-TTAACGTGCAGAACAAGAACAGCAGCT BHQ2
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to day 5, followed by a full oral course of doxycycline.
The patient was transferred from ICU to a standard
medical ward on day 5, and discharged on day 7. Six
sequential samples were available for analysis.
Patient 4, a British oil industry worker, presented with
uncomplicated falciparum malaria in Port Harcourt,
Nigeria, while working as a contractor in Nigeria and
Angola. Quinine therapy administered in Port Harcourt
failed to resolve a reported high parasitaemia, and the
patient was transferred to HTD, London, by his
employer, as a precaution. The patient reported previous
bouts of malaria, but dates were not specified. P. falci-
parum infection was confirmed, with an initial parasite
density of 0.5% on arrival in London. Oral QN therapy
was continued at HTD for 48 hours (five doses in total)
but poor response was again observed, necessitating a
switch to oral atovaquone-proguanil (AP) (four tablets
daily, for three days). Five sequential daily blood samples
were available for analysis. The patient was clinically
well by day 4 and was discharged before complete para-
site clearance, with the remaining AP dose to be taken
upon arrival in Nigeria.
All patients responded to treatment and were dis-
charged after clinical improvement and reduction of
parasite density to at or near zero.
Microscopic estimates of parasite density
Estimated parasite density for each patient before and
during treatment is shown in Table 2. PCT was extrapo-
lated from microscopy data for each patient, and esti-
mates of PCT of 120 h, 96 h and 120 h were obtained
for patients 1, 2 and 3, respectively. There were insuffi-
cient data points to estimate PCT for patient 4 by
microscopy. Due to the microscopic limit of detection
(50 parasites/μl), PCT estimated from microscopy data
does not give accurate results when the parasitaemia is
very low and thus an additional parameter, the time to
clearance of 95% of the starting parasites, PCT95, was
also estimated. Treatment response is partially depen-
dent on admission parasitaemia and this was taken into
account by estimation of the parasite reduction ratio
over 48 hours, PRR48h, for each patient. A log graph of
relative parasite density versus time was plotted in order
to compare PCT for each patient (Figure 1a). The
PCT95 values for the four patients were 49, 16, 45 and
56 hours respectively.
Estimating PCT by qPCR
Amplification of the HumTuBB gene was used to nor-
malize the qPCR for the amount of infected blood ana-
lysed in the reaction. Amplification of both PgMET and
HumTuBB was optimized for efficient hydrolysis probe
detection of both targets in the same assay tube. Figure
2 shows raw data output of the qPCR assay, as fluores-
cent signal in each of the two channels, versus cycle
number and a threshold set empirically by reference to
positive and negative controls run in the same assay.
The number of cycles of amplification of the human
gene required to cross the threshold level of fluores-
cence (cycle threshold value, CT) remained stable
throughout post-treatment follow-up, while the parasite
gene showed a daily decrease as parasite density fell
under treatment.
Cycle Threshold (CT) values were imported into a
Microsoft Excel spreadsheet for analysis. Difference in
CT (ΔCT) of the parasite target gene (PgMET) and the
CT of the human reference gene (HumTuBB) of the
same sample, was calculated as follows:
Δ Δ ΔC C CT T PgMET T HumTuBB= −( ) ( )
The change in ΔCT over time following treatment
(ΔΔCT ) was computed as:
ΔΔ Δ ΔC C CT n T n T( ) ( ) ( )= − 0
where n is time after treatment and time 0 is defined
as the time at which the pre-treatment diagnostic sam-
ple was taken, or if that was unavailable, as for patients
3 and 4, the time at which the first sample in our series
was taken.
The parasite density in each sample relative to the
calibrator sample (day 0) was then estimated using the
formula 2-ΔΔCT [10]. The relative parasite abundance
was plotted over time (Figure 1b). The qPCR plots are
similar to those based on microscopy data (Figure 1a)
Table 2 Parasite density by microscopy of daily blood samples from each patient
Parasite ID Origin Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Treatment
1 (OX007) Nigeria 3.2 2 0.004 0.001 0.0001 0 ND Quinine
2 (OX005) Ghana 3 2.4 0.02 0 (G)* 0 (G) ND ND Quinine
3 (OX006) Kenya 39* 25 24* 1.4 0.005 0.001 0 AS
4 Nigeria/
Angola
0.5 1.6 0.05 0.01 0.002 ND ND Quinine, AP
Densities are given as percentage parasitaemia (i.e. percentage of total erythrocytes counted that are infected) (G) denotes presence of gametocytes.
ND - not done, as patient previously discharged.
* samples were not available for qPCR.
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but provide additional quantitative data in the later sam-
ples (days 3, 4 post-treatment) due to the higher sensi-
tivity of qPCR.
The natural log of relative parasite abundance against
time was plotted for each patient and fitted well with a
simple linear model. Using this model of the parasite
clearance dynamics in each patient, we again calculated
PCT (with clearance defined as parasite density at 10-4%
that of the starting sample, i.e. a reduction of 106-fold),
PRR48 h and PCT95 parameters (Figure 3). These are
compared to parameter values derived directly from
microscopy and qPCR data in Table 3. For patients 1, 2
and 4 there is good agreement between the PRR48 h and
PC95 parameter values estimated directly from micro-
scopy or qPCR. Direct observation of PCT by qPCR was
not possible for these patients, as all were parasite posi-
tive in this assay at the time of discharge, even though
negative by microscopy. However, clearance time esti-
mates derived from extrapolating the log-linear model
to 10-4% of starting parasitaemia also agreed well with
microscopic observations, and this was true whether
microscopic or qPCR data were used to derive the line
of best fit (Table 3). The one exception was patient 3, in
that an observed clearance time by microscopy of 120 h
in this individual, and a log-linear extrapolation from
these data of 121 h, contrasts with a much longer
clearance time of 183 h from qPCR data extrapolated to
10-4% of starting parasitaemia. This suggests that cau-
tion is needed in applying this methodology to estimate
PCT, as opposed to reduction ratios, in patients with
severe malaria presenting as hyperparasitaemia.
Discussion
The current study presents the design and validation of
a rapid, highly sensitive and potentially high-throughput
assay to detect and quantify malaria parasites. Compared
to expert double-read microscopy, the assay successfully
detected and accurately measured malaria parasite den-
sities in four individual patients treated with different
anti-malarial regimens. The sensitivity, accuracy and
reproducibility of the PCT assay have been further
validated against the WHO International Standard for
P. falciparum DNA, which is essentially lyophilized
whole blood from a malaria patient, and thus provides
both human and parasite targets for our duplex qPCR
[14]. The assay can detect Plasmodium densities as low
as five parasites per μl of peripheral blood; parasite
DNA was detected in two of the post-treatment samples
that were reported negative by microscopy, and in a
third sample reported to harbour scanty gametocytes of
P. falciparum. This appears to be the first real-time PCR
assay specifically designed to measure parasite clearance
in follow-up of treated malaria patients, and has distinct
advantages over previous methods used for this purpose,
such as sybrG detection of 18 S ribosomal DNA
sequences [11]. The pgmet target has the advantage of
being equally suitable for amplifying all Plasmodium
species, and quantifies total parasite load in multi-spe-
cies infections. It is a relatively simple matter to adapt
the assay to any specific single parasite species of choice.
The assay was designed specifically for use with dried
blood-spot samples collected simply in field situations,
without measuring blood sample volumes, which would
then be transferred to a laboratory with qPCR capacity.
As a first step to validating this approach, the sensitivity,
specificity and quantitative accuracy of the assay has
Figure 1 Comparison of PCT Estimates from daily microscopy
versus qPCR. Upper panel depicts daily microscopy data. Initial
parasite density was converted into % of pre-treatment level. Patient
3 had very high initial parasitemia (39%). The poor response of
patient 4 over the initial 48 hr of QN treatment led to substitution
with AP. Lower panel depicts qPCR data, analysed using the ΔΔCT
calculation. Relative density of parasite DNA at each sample time
point was converted to percentage of starting abundance in order
to compare it with microscopy.
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been demonstrated here in a UK reference laboratory
for parasitology, against high quality microscopic diag-
nosis. The efficacy of anti-malarial treatment is typically
assessed by monitoring the clearance of parasites from
the peripheral blood, and the speed at which symptoms
and signs resolve. The utility of the assay to compare
anti-malarial treatment response in different patients in
this small pilot study has been demonstrated, and clear
differences shown in PCT, PRR48 h and PCT95 among
the four patients (Table 3, Figure 3). The ability to dis-
cern details of parasite clearance dynamics in individuals
demonstrates the likely utility of this assay for detection
of P. falciparum isolates with reduced sensitivity to
ACT treatment. The qPCR method is now being suc-
cessfully used to estimate PCT and PRR48 h using DNA
extracted from dried filter paper blood spots. These
have been collected during follow-up of a randomised
efficacy study of two ACT regimens in 300 children
with malaria in Mbita, western Kenya in 2009, similar to
earlier studies in this area [15].
Dondorp and colleagues [6] used closely-spaced
microscopic examination of blood films in small groups
of malaria patients to demonstrate unusually slow para-
site clearance time in some P. falciparum infected indi-
viduals from western Cambodia treated with AS. This
parasite clearance phenotype could be explained by heri-
table changes in parasite growth rate, but may also indi-
cate evolution of new mechanisms of resistance to
artemisinin compounds [16,17]. The duplex qPCR assay,
capable of relatively high throughput, and thus incor-
poration in larger studies, should assist in performing
association studies to identify candidate genetic markers
in P. falciparum of the artemisinin slow clearing parasite
phenotype. Such markers, once validated, would be of
Figure 3 Best fit log-linear parasite clearance curves for each
patient. The graph shows the Parasite Reduction Ratio (PRR) for
each anti-malarial treatment, estimated from qPCR data. PRR is the
ratio in parasite density between admission and 48 hours post-
treatment. R2 (coefficient of determination) reflects the goodness of
fit of the log linear regression.
Figure 2 Real-time amplification plot from duplex qPCR. Real-time amplification plot of sequential samples (run in triplicate) from patient 2
at 0, 24, 48, 72 and 96 hours after QN treatment using primers for the parasite target gene (left) and the human normalizer gene (right). Each
trio of curves represents DNA amplification from peripheral blood of patient 2 taken at a different time point.
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enormous benefit in monitoring and containing resis-
tance to ACT therapy.
Study protocols are now being developed that incorpo-
rate the qPCR PCT assay as an endpoint in large scale
clinical trials of ACT efficacy in Africa. Initial testing of
the assay on filter-paper DNA has shown promising
results, and thus there is optimism that the method can
be adopted to detect the phenotypic characteristics of
parasites in clinical trials during the three days immedi-
ately after treatment. As the proportion of positive
microscopy readings for ACT-treated patients on day 3 is
generally less than 3% [7], a particular advantage of the
qPCR PCT assay is its potential to detect and quantify
parasites in many more patients on that day (Figure 3).
It is perhaps not surprising that the performance of
the qPCR assay was markedly different in patient 3, who
presented with extreme hyperparasitaemia, but recov-
ered under AS monotherapy. There appeared to be a
persistence of parasitized erythrocytes as detected by
PCR for longer, and at greater estimated densities, than
was expected from the microscopy results. It is unlikely
the presence of peripheral gametocytes were responsible
for this qPCR result, as the microscopists did not
indicate the presence of sexual stages of P. falciparum,
an observation routinely recorded. The higher parasite
density estimated by qPCR could be due to the well-
described circulation of more mature parasite forms,
with significantly higher DNA content per cell, in severe
malaria. Dead parasites may also contain detectable
parasite DNA, but are not expected to circulate in a
patient with an intact spleen, although pigment-positive
phagocytes may also contain some detectable parasite
DNA in parasites with very high parasitaemia. Dead
parasites appear to be of no consequence in compari-
sons of qPCR-derived parasite densities with microscopy
in uncomplicated P. falciparum infections in which
parasite density is in the normal range [11]. Thus, it is
expected that the qPCR assay will be most useful in stu-
dies of treatment response in uncomplicated malaria
patients in the absence of hyperparasitaemia.
Conclusions
This study provides proof of principle that a duplex
fluorescent qPCR assay can be deployed to robustly esti-
mate the rate of parasite clearance in treated malaria
patients. The particular assay used here has the advan-
tage of deploying a parasite target sequence that is iden-
tical in all Plasmodium species investigated and thus
provides an estimate of total parasite burden. The
method could be easily adapted to use specific amplifi-
cation targets for each Plasmodium species.
List of abbreviations
ACT: artemisinin combination therapy; AP: atovaquone-proguanil; HTD:
Hospital for Tropical Diseases, London; HumTuBB: human b-tubulin gene
sequence; ICU: intensive care unit; PCT: parasite clearance time; PgMET:
Plasmodium genus methionine tRNA gene sequence; PRR: parasite reduction
ratio; QN; quinine; qPCR: quantitative (real-time) PCR
Acknowledgements
This work was supported by the EDCTP project IP.2007.31060.002, “An
integrated approach to clinical trials, capacity building and networking in
West Africa”, co-ordinated by Abdoulaye Djimde, University of Bamako. CJS
is supported by the UK Health Protection Agency. SDP is supported by the
Foundation for Innovative New Diagnostics. PLC is supported by the UCL
Hospitals Comprehensive Biomedical Research Centre Infection Theme.
These funding sources played no role in the collection, analysis or
interpretation of the data; nor in the writing of the manuscript, or in the
decision to submit the manuscript for publication. We thank Maggie
Armstrong for assistance in accessing patients’ notes.
Author details
1Faculty of Infectious and Tropical Diseases, London School of Hygiene &
Tropical Medicine (LSHTM), Keppel St, London, WC1E 7HT, UK. 2Hospital for
Tropical Diseases, Mortimer Market Centre, Capper St, London, WC1E 6JB UK.
3HPA Malaria Reference Laboratory, LSHTM, Keppel St, London, WC1E 7HT,
UK.
Authors’ contributions
KB designed the PCT assay, carried out experiments and wrote the first draft
of the manuscript. RLH designed the assay, processed samples, and
contributed to writing the second draft of the manuscript. ACE, RB, SW and
PLC were responsible for patient care, and contributed to the second draft
of the manuscript. JW coordinated microscopy, and oversaw quality control
Table 3 Comparison of measured and estimated
parameters of parasite clearance
A. PCT (hr):
Patient (ID) Drug Micr.
observed
qPCR* observed Micr.
LL
qPCR
LL
1 (OX007) QN 120 - 122 134
2 (OX005) QN 96 - 87 89
3 (OX006) AS 120 - 121 183
4 QN; AP - - 220 199
B. PRR48 h (ratio, no units):
Patient (ID) Drug Micr.
observed
qPCR * observed Micr.
LL
qPCR
LL
1 (OX007) QN 80 30 100 50
2 (OX005) QN 100 000 100 000 25 000 25 000
3 (OX006) AS 50 14 100 14
4 QN; AP 10 7 10 10
C. PCT95 (hr):
Patient (ID)
Drug
Drug Micr.
observed
qPCR * observed Micr.
LL
qPCR
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hence PCT was not directly observed by RT-PCR.
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